Chronic cutaneous lupus erythematosus
disease diseaseOn this page
Also known as cutaneous lupus erythematosus, chronic
Summary
Chronic cutaneous lupus erythematosus (MONDO:0015574) is a disease (an umbrella term covering 5 Mondo subtypes) and 3 clinical trials. Top therapeutic interventions include litifilimab. A subtype of cutaneous lupus erythematosus — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Umbrella term: 5 Mondo subtypes
- Clinical trials: 3
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | chronic cutaneous lupus erythematosus |
| Mondo ID | MONDO:0015574 |
| Orphanet | 163531 |
| ICD-11 | 1849568465 |
| GARD | 0020043 |
| MedDRA | 10057929 |
| Is cancer (heuristic) | no |
Also known as: cutaneous lupus erythematosus, chronic
Disease family
This is a subtype of cutaneous lupus erythematosus. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › connective tissue disorder › rheumatic disorder › lupus erythematosus › cutaneous lupus erythematosus › chronic cutaneous lupus erythematosus
Related subtypes (3): subacute cutaneous lupus erythematosus, Rowell syndrome, bullous systemic lupus erythematosus
Subtypes (5): chilblain lupus, discoid lupus erythematosus, hypertrophic or verrucous lupus erythematosus, lupus erythematosus tumidus, lupus erythematosus panniculitis
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 3.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2/PHASE3 | 1 |
| PHASE3 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT05531565 | PHASE2/PHASE3 | RECRUITING | A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus |
| NCT06044337 | PHASE3 | ENROLLING_BY_INVITATION | A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus |
| NCT06980805 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| LITIFILIMAB | 3 | 2 |
Related Atlas pages
- Drugs: Litifilimab